Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Pacific Biosciences of California’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001299130-26-000122
| (In thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Proceeds from disposal of assets | 50,000 | — |
| Payment for waiver of milestone obligation | (1,900) | — |
| Purchases of property and equipment | (4,598) | (1,939) |
| Purchases of intangible assets | (5,000) | (5,000) |
| Purchase of patent license | (2,056) | — |
| Purchases of investments | (57,547) | (117,992) |
| Maturities of investments | 97,031 | 195,448 |
Item 1. Financial Statements (unaudited):
FAQ
- What is Pacific Biosciences of California's capex?
- Pacific Biosciences of California (PACB) reported capex of $1.56M in Q2 2026.
- How has Pacific Biosciences of California's capex changed year-over-year?
- Pacific Biosciences of California's capex increased by 182.7% year-over-year, from $550K to $1.56M.
- What is the long-term trend for Pacific Biosciences of California's capex?
- Over 3 years (2021 to 2025), Pacific Biosciences of California's capex has grown at a -22.1% compound annual growth rate (CAGR), from $5.93M to $2.8M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Pacific Biosciences of California's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude